» Articles » PMID: 39450890

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran -Active KAT6AB Inhibitor

Abstract

KAT6A and KAT6B genes are two closely related lysine acetyltransferases that transfer an acetyl group from acetyl coenzyme A (AcCoA) to lysine residues of target histone substrates, hence playing a key role in chromatin regulation. KAT6A and KAT6B genes are frequently amplified in various cancer types. In breast cancer, the 8p11-p12 amplicon occurs in 12-15% of cases, resulting in elevated copy numbers and expression levels of chromatin modifiers like KAT6A. Here, we report the discovery of a new acylsulfonamide-benzofuran series as a novel structural class for KAT6A/B inhibition. These compounds were identified through high-throughput screening and subsequently optimized using molecular modeling and cocrystal structure determination. The final tool compound, BAY-184 (), was successfully validated in an proof-of-concept study.

Citing Articles

Enhancing Antileishmanial Activity of Amidoxime-Based Compounds Bearing a 4,5-Dihydrofuran Scaffold: In Vitro Screening Against .

Maia Santos Urbancg Moncorvo F, Avendano Leon O, Curti C, Kabri Y, Redon S, Torres-Santos E Molecules. 2024; 29(22).

PMID: 39598858 PMC: 11597885. DOI: 10.3390/molecules29225469.

References
1.
Jabs V, Edlund K, Konig H, Grinberg M, Madjar K, Rahnenfuhrer J . Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS One. 2017; 12(11):e0187246. PMC: 5675410. DOI: 10.1371/journal.pone.0187246. View

2.
Hu Z, Zhou J, Jiang J, Yuan J, Zhang Y, Wei X . Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nat Commun. 2019; 10(1):733. PMC: 6374416. DOI: 10.1038/s41467-019-08554-x. View

3.
McCullough C, Marmorstein R . In Vitro Activity Assays for MYST Histone Acetyltransferases and Adaptation for High-Throughput Inhibitor Screening. Methods Enzymol. 2016; 573:139-60. PMC: 5072368. DOI: 10.1016/bs.mie.2016.01.016. View

4.
Hirsch C, Wrana J, Dent S . KATapulting toward Pluripotency and Cancer. J Mol Biol. 2016; 429(13):1958-1977. PMC: 5382138. DOI: 10.1016/j.jmb.2016.09.023. View

5.
Yu L, Liang Y, Cao X, Wang X, Gao H, Lin S . Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene. 2016; 36(20):2910-2918. PMC: 5436938. DOI: 10.1038/onc.2016.433. View